期刊
EXPERT REVIEW OF VACCINES
卷 12, 期 3, 页码 323-332出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERV.13.1
关键词
adenovirus gene transfer vector; antidrug immunoglobulin; butyrylcholinesterase; clinical trial; cocaine abuse; cocaine hydrolase; metabolism-based therapies; monoclonal antibody; vaccine
类别
资金
- National Institute for Drug Abuse [P1 DA031340, R01 DA023979]
- Mayo Foundation
- Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development,
- NIH [R01 DA030338]
This review addresses potential new treatments for stimulant drugs of abuse, especially cocaine. Clinical trials of vaccines against cocaine and nicotine have been completed with the generally encouraging result that subjects showing high titers of antidrug antibody experience a reduction in drug reward, which may aid in cessation. New vaccine technologies, including gene transfer of highly optimized monoclonal antibodies, are likely to improve such outcomes further. In the special case of cocaine abuse, a metabolic enzyme is emerging as an alternative or added therapeutic intervention, which would also involve gene transfer. Such approaches still require extensive studies of safety and efficacy, but they may eventually contribute to a robust form of in vivo drug interception that greatly reduces the risks of addiction relapse.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据